Displaying drugs 2001 - 2025 of 3443 in total
AP-102
Investigational
Matched Iupac: … (2S,3R)-2-{[(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-(4-amino-3-iodophenyl)propanamido]-10-(4-aminobutyl …
ET-101
Investigational
MB-107
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Investigational
Silatecan
Silatecan has been used in trials studying the treatment of GBM, Tumors, Gliosarcoma, Solid Malignancies, and Glioblastoma Multiforme, among others.
Investigational
Matched Iupac: … }.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione ... (19S)-10-(tert-butyldimethylsilyl)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11 …
Ornidazole
Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.
Investigational
Matched Mixtures name: … ORNISASIN 500 MG/500 MG FILM TABLET, 10 ADET ... ORCIPOL 500 MG/500 MG FILM TABLET, 10 ADET ... SIPROFORTE 500 MG/ 500 MG FILM TABLET , 10 ADET …
Matched Products: … ORNITOP 500 MG FILM TABLET, 10 ADET ... BITERAL 500 MG FILM KAPLI TABLET, 10 ADET ... ALBITROL 500 MG FİLM KAPLI TABLET, 10 ADET …
Matched Products: … ORNITOP 500 MG FILM TABLET, 10 ADET ... BITERAL 500 MG FILM KAPLI TABLET, 10 ADET ... ALBITROL 500 MG FİLM KAPLI TABLET, 10 ADET …
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Nanaomycin D
Experimental
Matched Iupac: … (11R,15S,17S)-4-hydroxy-17-methyl-12,16-dioxatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-1(10),3(8), …
Intoplicine
Intoplicine has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Iupac: … -1(10),2,4,6,8,12(17),13,15-octaen-5-ol ... 16-{[3-(dimethylamino)propyl]amino}-13-methyl-11,15-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca …
Becatecarin
Becatecarin is a derivative of rebeccamycin.
Investigational
Matched Iupac: … {4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaene-12,14-dione ... ,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^ …
Apc001PE
Investigational
SQ-109
SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Investigational
PR-104
Investigational
PX-102
PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).
Investigational
GI-101
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc.
Investigational
SP-101
Investigational
CM-101
Investigational
GS-100
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Investigational
Efonidipine
Efonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis...
Experimental
Sonpiretigene isteparvovec
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
Investigational
MORAb-066
MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Investigational
Zanzalintinib
Investigational
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Displaying drugs 2001 - 2025 of 3443 in total